Table 3 Course of Quality of Life as assessed in 21 ovarian cancer patients with the EORTC Quality of Life core questionnaire (QLQ-C30)
EORTC QLQ-C30c | |||||||
|---|---|---|---|---|---|---|---|
| Â | Baselinea | CT3b | CT6 | AC1b | AC2 | constant term/ beta coefficient | |
Physical Functioning (PF) | 53.7 (27.3) | 62.0 | 65.9 | 78.5 | 93.9 (8.7) | 50.1/5.9 | t = 7.31; p < 0.001 |
Social Functioning (SF) | 34.1 (26.6) | 53.9 | 63.7 | 76.5 | 86.1 (15.6) | 34.3/7.2 | t = 7.29; p < 0.001 |
Role Functioning (RF) | 40.5 (35.2) | 36.3 | 47.1 | 62.0 | 77.8 (27.8) | 32.0/5.0 | t = 3.74; p < 0.001 |
Emotional Functioning (EF) | 47.6 (24.6) | 64.2 | 69.6 | 79.9 | 87.5 (15.7) | 49.0/5.3 | t = 5.93; p < 0.001 |
Cognitive Functioning (CF) | 77.0 (25.5) | 73.5 | 86.3 | 86.3 | 90.3 (16.6) | 75.0/2.0 | t = 2.22; p = 0.031 |
Global QOL (GQOL) | 47.5 (14.3) | 56.4 | 59.8 | 58.3 | 60.4 (29.3) | 49.0/1.9 | t = 2.405; p = 0.019 |
Fatigue (FA) | 66.1 (28.2) | 51.6 | 51.6 | 33.3 | 16.2 (16.8) | 67.2/-6.3 | t = -6.18; p < 0.001 |
Nausea/Vomiting (NV) | 23.8 (30.1) | 15.6 | 14.7 | 2.8 | 5.6 (13.0) | 23.1/-3.0 | t = -3.35; p = 0.002 |
Pain (PA) | 46.0 (37.6) | 35.3 | 33.3 | 25.9 | 10.6 (13.5) | 47.9/-4.8 | t = -4.18; p < 0.001 |
Dyspnoe (DY) | 19.0 (34.3) | 13.7 | 23.5 | 7.4 | 8.3 (20.7) | 18.5/-1.5 | t = -1.36; p = 0.178 |
Sleeping Disturbances (SD) | 38.1 (38.4) | 35.3 | 23.5 | 55.6 | 13.9 (33.2) | 39.5/-3.1 | t = -1.91; p = 0.062 |
Appetite Loss (AP) | 57.1 (42.4) | 5.9 | 21.6 | 7.4 | 0.0 (0.0) | 31.0/-4.0 | t = -3.04; p = 0.006 |
Constipation (CO) | 25.0 (35.7) | 15.7 | 27.5 | 14.8 | 6.1 (20.1) | 23.9/-2.0 | t = -1.60; p = 0.116 |
Diarrhea (DI) | 16.7 (29.6) | 11.8 | 8.3 | 9.3 | 0.0 (0.0) | 12.2/-0.7 | t = -1.43; p = 0.167 |
Financial Impact (FI) | 19.0 (30.9) | 25.5 | 13.7 | 5.9 | 2.8 (9.6) | 23.8/-2.9 | t = -3.12; p = 0.003 |